Progress, prospects, and problems in Epstein-Barr virus vaccine development

Current Opinion in Virology

Volumn 6, Issue 1, 2014, Pages 1-5

  Balfour Jr , Henry H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS VACCINE; VIRUS VACCINE;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; CONSENSUS; DRUG DEVELOPMENT; DRUG EFFICACY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; MONONUCLEOSIS; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMATE; PRIORITY JOURNAL; PROPHYLAXIS; UNITED STATES; ANIMAL; CLINICAL TRIAL (TOPIC); EPSTEIN-BARR VIRUS INFECTIONS; IMMUNOLOGY; INFECTIOUS MONONUCLEOSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; INFECTIOUS MONONUCLEOSIS; VIRAL VACCINES;

EID: 84896525418     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.02.005     Document Type: Review

References (31)

1. M.A. Epstein Epstein-Barr virus - is it time to develop a vaccine program? J Natl Cancer Inst 56 1976 697 700
2. J.I. Cohen, A.S. Fauci, H. Varmus, and G.J. Nabel Epstein-Barr virus: an important vaccine target for cancer prevention Sci Transl Med 3 2011 107fs7
3. S.Y. Gu, T.M. Huang, L. Ruan, Y.H. Miao, H. Lu, C.M. Chu, M. Motz, and H. Wolf First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen Dev Biol Stand 84 1995 171 177
4. D.M. Maurer, B. Harrington, and J.M. Lane Smallpox vaccine: contraindications, administration, and adverse reactions Am Fam Physician 68 2003 889 896
5. W.T. Jackman, K.A. Mann, H.J. Hoffmann, and R.R. Spaete Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine Vaccine 17 1999 660 668
6. M. Moutschen, P. Leonard, E.M. Sokal, F. Smets, M. Haumont, P. Mazzu, A. Bollen, F. Denamur, P. Peeters, and G. Dubin et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults Vaccine 25 2007 4697 4705
7. E.M. Sokal, K. Hoppenbrouwers, C. Vandermeulen, M. Moutschen, P. Leonard, A. Moreels, M. Haumont, A. Bollen, F. Smets, and M. Denis Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults J Infect Dis 196 2007 1749 1753
8. L. Rees, E.J. Tizard, A.J. Morgan, W.D. Cubitt, S. Finerty, T.A. Oyewole-Eletu, K. Owen, C. Royed, S.J. Stevens, and R.C. Shroff et al. A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation Transplantation 88 2009 1025 1029
9. R. Khanna, S.R. Burrows, M.G. Kurilla, C.A. Jacob, I.S. Misko, T.B. Sculley, E. Kieff, and D.J. Moss Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development J Exp Med 176 1992 169 176
10. S.R. Burrows, T.B. Sculley, I.S. Misko, C. Schmidt, and D.J. Moss An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3) J Exp Med 171 1990 345 349
11. + T-cell peptide epitope-based vaccine for infectious mononucleosis J Virol 82 2008 1448 1457
12. E.P. Hui, G.S. Taylor, H. Jia, B.B. Ma, S.L. Chan, R. Ho, W.L. Wong, S. Wilson, B.F. Johnson, and C. Edwards et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients Cancer Res 73 2013 1676 1688
13. H.H. Balfour Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis - and what else? J Infect Dis 196 2007 1724 1726
14. G.R. Nemerow, C. Mold, V.K. Schwend, V. Tollefson, and N.R. Cooper Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d J Virol 61 1987 1416 1420
15. D.J. Moss, and J.H. Pope Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro J Gen Virol 17 1972 233 236
16. J. Sashihara, P.D. Burbelo, B. Savoldo, T.C. Pierson, and J.I. Cohen Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay Virology 391 2009 249 256
17. A. Moghaddam, M. Rosenzweig, D. Lee-Parritz, B. Annis, R.P. Johnson, and F. Wang An animal model for acute and persistent Epstein-Barr virus infection Science 276 1997 2030 2033
18. J. Sashihara, Y. Hoshino, J.J. Bowman, T. Krogmann, P.D. Burbelo, V.M. Coffield, K. Kamrud, and J.I. Cohen Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge PLoS Pathog 7 2011 e1002308
19. H.H. Balfour Jr., O.A. Odumade, D.O. Schmeling, B.D. Mullan, J.A. Ed, J.A. Knight, H.E. Vezina, W. Thomas, and K.A. Hogquist Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students J Infect Dis 207 2013 80 88
20. H.H. Balfour Jr., C.J. Holman, K.M. Hokanson, M.M. Lelonek, J.E. Giesbrecht, D.R. White, D.O. Schmeling, C. Webb, W. Cavert, and D.H. Wang et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis J Infect Dis 192 2005 1505 1512
21. C.J. Holman, A.B. Karger, B.D. Mullan, R.C. Brundage, and H.H. Balfour Jr. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder Clin Transplant 26 2012 741 747
22. J.A. Kanakry, H. Li, L.L. Gellert, M.V. Lemas, W.S. Hsieh, F. Hong, K.L. Tan, R.D. Gascoyne, L.I. Gordon, and R.I. Fisher et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial Blood 121 2013 3547 3553
23. J.J. Rainey, D. Omenah, P.O. Sumba, A.M. Moormann, R. Rochford, and M.L. Wilson Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya Int J Cancer 120 2007 121 127
24. H. Hjalgrim, K. Rostgaard, P.C. Johnson, A. Lake, L. Shield, A.M. Little, K. Ekstrom-Smedby, H.O. Adami, B. Glimelius, and S. Hamilton-Dutoit et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma Proc Natl Acad Sci U S A 107 2010 6400 6405
25. C.V. Sumaya, L.W. Myers, and G.W. Ellison Epstein-Barr virus antibodies in multiple sclerosis Arch Neurol 37 1980 94 96
26. K.L. Munger, L.I. Levin, E.J. O'Reilly, K.I. Falk, and A. Ascherio Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel Mult Scler 17 2011 1185 1193
27. A.E. Handel, A.J. Williamson, G. Disanto, L. Handunnetthi, G. Giovannoni, and S.V. Ramagopalan An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis PLoS ONE 5 2010
28. + T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis PLoS Pathog 9 2013 e1003220
29. S.L. Hauser, E. Waubant, D.L. Arnold, T. Vollmer, J. Antel, R.J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, and S. Agarwal et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688
30. J.I. Cohen, E.S. Mocarski, N. Raab-Traub, L. Corey, and G.J. Nabel The need and challenges for development of an Epstein-Barr virus vaccine Vaccine 31 Suppl. 2013 B194 B196
31. H.H. Balfour Jr., F. Sifakis, J.A. Sliman, J.A. Knight, D.O. Schmeling, and W. Thomas Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition J Infect Dis 208 2013 1286 1293